The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
RETRACTED ARTICLE: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
Abstract
The anti-CD38 monoclonal antibody SAR650984 (SAR) is showing promising clinical activity in treatment of relapsed and refractory multiple myeloma (MM). Besides effector-mediated antibody-dependent cellular cytotoxicity and complement-mediated cytotoxicity, we here define molecular mechanisms of SAR-directed MM cell death and enhanced anti-MM activity triggered by SAR with Pomalidomide (Pom). Without Fc-cross-linking agents or effector cells, SAR specifically induces homotypic aggregation (HA)-associated cell death in MM cells dependent on the level of cell surface CD38 expression, actin cytoskeleton and membrane lipid raft. SAR and its F(ab)'2 fragments trigger caspase 3/7-dependent apoptosis in MM cells highly expressing CD38, even with p53 mutation. Importantly, SAR specifically induces lysosome-dependent cell death (LCD) by enlarging lysosomes and increasing lysosomal membrane permeabilization associated with leakage of cathepsin B and LAMP-1, regardless of the presence of interleukin-6 or bone marrow stromal cells. Conversely, the lysosomal vacuolar H+-ATPase inhibitor blocks SAR-induced LCD. SAR further upregulates reactive oxygen species. Pom enhances SAR-induced direct and indirect killing even in MM cells resistant to Pom/Len. Taken together, SAR is the first therapeutic monoclonal antibody mediating direct cytotoxicity against MM cells via multiple mechanisms of action. Our data show that Pom augments both direct and effector cell-mediated MM cytotoxicity of SAR, providing the framework for combination clinical trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Isatuximab has been shown to directly induce apoptosis in MM cells without the need for crosslinking agents or effector cells. This unique ability contributes to its effectiveness in killing MM cells [167, 168].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [168]
Citations
Cites
de Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Self-citationLysosomal cell death at a glance
Aits, S., & Jäättelä, M. (2013) · Journal of Cell Science · doi:10.1242/jcs.091181 · Cited by 667
Hsp70 stabilizes lysosomes and reverts Niemann–Pick disease-associated lysosomal pathology
Kirkegaard, T., Roth, A. G., Petersen, N. H. T., Mahalka, A. K., Olsen, O. D., Moilanen, I., Zylicz, A., Knudsen, J., Sandhoff, K., Arenz, C., et al. (2010) · Nature · doi:10.1038/nature08710 · Cited by 519
Tai, Y., Mayes, P. A., Acharya, C., Zhong, M. Y., Cea, M., Cagnetta, A., Craigen, J. L., Yates, J. W., Gliddon, L., Fieles, W. E., et al. (2014) · Blood · doi:10.1182/blood-2013-10-535088 · Cited by 492
Self-citationTai, Y., Dillon, M., Song, W., Leiba, M., Li, X.-F., Burger, P., Lee, A. I., Podar, K., Hideshima, T., Rice, A. G., et al. (2007) · Blood · doi:10.1182/blood-2007-08-107292 · Cited by 472
Self-citationDroga-Mazovec, G., Bojič, L., Petelin, A., Ivanova, S., Romih, R., Repnik, U., Salvesen, G. S., Stoka, V., Turk, V., & Turk, B. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802513200 · Cited by 399
Petersen, N. H. T., Olsen, O. D., Groth‐Pedersen, L., Ellegaard, A., Bilgin, M., Redmer, S., Ostenfeld, M. S., Ulanet, D., Dovmark, T. H., Lønborg, A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.003 · Cited by 344
Zonder, J. A., Mohrbacher, A. F., Singhal, S., van Rhee, F., Bensinger, W. I., Ding, H., Fry, J., Afar, D. E. H., & Singhal, A. K. (2012) · Blood · doi:10.1182/blood-2011-06-360552 · Cited by 342
Deckert, J., Wetzel, M.-C., Bartle, L. M., Skaletskaya, A., Goldmacher, V. S., Vallée, F., Zhou-Liu, Q., Ferrari, P., Pouzieux, S., Lahoute, C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0695 · Cited by 333
Tai, Y.-T., Landesman, Y., Acharya, C., Calle, Y., Zhong, M., Cea, M., Tannenbaum, D., Cagnetta, A., Reagan, M. R., Munshi, A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.115 · Cited by 310
Self-citation
Cited by
Sorted by citations
Attal, M., Richardson, P. G. G., Rajkumar, S. V., Miguel, J. F. S., Beksaç, M., Špıčka, I., Leleu, X. P., Schjesvold, F. H., Moreau, P., Dimopoulos, M. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32556-5 · Cited by 648
Self-citationCD38 antibodies in multiple myeloma: back to the future
van de Donk, N. W. C. J., Richardson, P. G. G., & Malavasi, F. (2017) · Blood · doi:10.1182/blood-2017-06-740944 · Cited by 495
Self-citationMoreau, P., Dimopoulos, M.-A., Mikhael, J., Yong, K., Capra, M., Facon, T., Hajek, R., Špička, I., Baker, R., Kim, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00592-4 · Cited by 392
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
van de Donk, N. W. C. J., & Usmani, S. Z. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02134 · Cited by 357
Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond
van de Donk, N. W. C. J., Janmaat, M. L., Mutis, T., Lammerts van Bueren, J. J., Ahmadi, T., Sasser, A. K., Lokhorst, H. M., & Parren, P. W. H. I. (2016) · Immunological Reviews · doi:10.1111/imr.12389 · Cited by 353
Tai, Y., Acharya, C., An, G., Moschetta, M., Zhong, M. Y., Feng, X., Cea, M., Cagnetta, A., Wen, K., van Eenennaam, H., et al. (2016) · Blood · doi:10.1182/blood-2016-01-691162 · Cited by 352
Self-citationOverdijk, M. B., Jansen, J. H. M., Nederend, M., Lammerts van Bueren, J. J., Groen, R. W. J., Parren, P. W. H. I., Leusen, J. H. W., & Boross, P. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501351 · Cited by 297
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Facon, T., Dimopoulos, M.-A., Leleu, X. P., Beksac, M., Pour, L., Hájek, R., Liu, Z., Minarik, J., Moreau, P., Romejko-Jarosinska, J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2400712 · Cited by 284
Feng, X., Zhang, L., Acharya, C., An, G., Wen, K., Qiu, L., Munshi, N. C., Tai, Y., & Anderson, K. C. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3192 · Cited by 252
Self-citationMultiple Myeloma: Available Therapies and Causes of Drug Resistance
Pinto, V., Bergantim, R., Caires, H. R., Seca, H., Guimarães, J. E., & Vasconcelos, M. H. (2020) · Cancers · doi:10.3390/cancers12020407 · Cited by 241
The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
Moreno, L., Pérez, C., Zabaleta, A., Manrique, I., Alignani, D., Ajona, D., Blanco, L., Lasa, M., Maiso, P., Rodríguez, I., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1597 · Cited by 221
Serrano‐Puebla, A., & Boya, P. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12966 · Cited by 204
Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication
An, G., Acharya, C., Feng, X., Wen, K., Zhong, M., Zhang, L., Munshi, N. C., Qiu, L., Tai, Y., & Anderson, K. C. (2016) · Blood · doi:10.1182/blood-2016-03-707547 · Cited by 188
Self-citationCD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
Morandi, F., Horenstein, A. L., Costa, F., Giuliani, N., Pistoia, V., & Malavasi, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02722 · Cited by 176
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
Martin, T. G., Corzo, K., Chiron, M., van de Velde, H., Abbadessa, G., Campana, F., Solanki, M., Meng, R., Lee, H., Wiederschain, D., et al. (2019) · Cells · doi:10.3390/cells8121522 · Cited by 166
Self-citationGoldschmidt, H., Mai, E. K., Bertsch, U., Fenk, R. R., Nievergall, E., Tichy, D., Besemer, B., Dürig, J., Schroers, R., von Metzler, I., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00263-0 · Cited by 167
Emerging immunotherapies in multiple myeloma
Shah, U. A., & Mailankody, S. (2020) · BMJ · doi:10.1136/bmj.m3176 · Cited by 160
Richardson, P. G. G., Perrot, A., Miguel, J. F. S., Beksaç, M., Spicka, I., Leleu, X., Schjesvold, F., Moreau, P., Dimopoulos, M. A., Huang, J. S.-Y., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00019-5 · Cited by 129
Self-citationMechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
Saltarella, I., Desantis, V., Melaccio, A., Solimando, A. G., Lamanuzzi, A., Ria, R., Storlazzi, C. T., Mariggiò, M. A., Vacca, A., & Frassanito, M. A. (2020) · Cells · doi:10.3390/cells9010167 · Cited by 127
Leleu, X. P., Hulin, C., Lambert, J., Bobin, A., Perrot, A., Karlin, L., Roussel, M., Montes, L., Chérel, B., Chalopin, T., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03050-2 · Cited by 121
Zhu, C. Y., Song, Z., Wang, A., Srinivasan, S. S., Yang, G., Greco, R., Theilhaber, J., Shehu, E., Wu, L., Yang, Z., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01771 · Cited by 117
Self-citationThe role of complement in the mechanism of action of therapeutic anti-cancer mAbs
Golay, J., & Taylor, R. P. (2020) · Antibodies · doi:10.3390/antib9040058 · Cited by 104
Bhatt, P. K., Kloock, C., & Comenzo, R. L. (2023) · Current Oncology · doi:10.3390/curroncol30020179 · Cited by 105
Immunomodulatory effects of CD38-targeting antibodies
van de Donk, N. W. C. J. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.04.005 · Cited by 96
B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma
Tai, Y., & Anderson, K. C. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1641196 · Cited by 94
Self-citationTypical and Atypical Inducers of Lysosomal Cell Death: A Promising Anticancer Strategy
Domagała, A., Fidyt, K., Bobrowicz, M., Stachura, J., Szczygiel, K., & Firczuk, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082256 · Cited by 96
Mikhael, J. R., Richardson, P. G. G., Usmani, S. Z., Raje, N. S., Bensinger, W., Karanes, C., Campana, F., Kanagavel, D., Dubin, F., Liu, Q., et al. (2019) · Blood · doi:10.1182/blood-2019-02-895193 · Cited by 90
Self-citationAnti CD38 monoclonal antibodies for multiple myeloma treatment
Gozzetti, A., Ciofini, S., Simoncelli, M., Santoni, A., Pacelli, P., Raspadori, D., & Bocchia, M. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2052658 · Cited by 89
Morandi, F., Airoldi, I., Marimpietri, D., Bracci, C., Faini, A. C., & Gramignoli, R. (2019) · Cells · doi:10.3390/cells8121527 · Cited by 88
Mikhael, J. R., Belhadj‐Merzoug, K., Hulin, C., Vincent, L., Moreau, P., Gasparetto, C., Pour, L., Špıčka, I., Vij, R., Zonder, J. A., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00478-4 · Cited by 88
Multiple myeloma: signaling pathways and targeted therapy
Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90
Dimopoulos, M. A., Bringhen, S., Anttila, P., Capra, M., Cavo, M., Cole, C. E., Gasparetto, C., Hungria, V., Jenner, M. W., Vorobyev, V. I., et al. (2020) · Blood · doi:10.1182/blood.2020008209 · Cited by 84
Dhillon, S. (2020) · Drugs · doi:10.1007/s40265-020-01311-1 · Cited by 79
Dimopoulos, M. A., Leleu, X. P., Moreau, P., Richardson, P. G. G., Liberati, A. M., Harrison, S. J., Prince, H. M., Ocio, E. M., Assadourian, S., Campana, F., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0868-z · Cited by 73
Self-citationRichardson, P. G. G., Attal, M., Campana, F., Le-Guennec, S., Hui, A., Risse, M., Corzo, K. P., & Anderson, K. C. (2017) · Future Oncology · doi:10.2217/fon-2017-0616 · Cited by 71
Self-citationCD38 Mediates Lung Fibrosis by Promoting Alveolar Epithelial Cell Aging
Cui, H., Xie, N., Banerjee, S., Dey, T., Liu, R.-M., Antony, V. B., Sanders, Y. Y., Adams, T. S., Gómez, J. L., Thannickal, V. J., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202109-2151oc · Cited by 72
Leleu, X. P., Martin, T. G., Weisel, K. C., Schjesvold, F. H., Iida, S., Malavasi, F., Manier, S., Min, C., Ocio, E. M., Pawlyn, C., et al. (2022) · Annals of Hematology · doi:10.1007/s00277-022-04917-5 · Cited by 69
Self-citationMatula, Z., Mikala, G., Lukácsi, S., Matkó, J., Kovács, T., Monostori, É., Uher, F., & Valyi-Nagy, I. T. (2021) · Cancers · doi:10.3390/cancers13143461 · Cited by 68
Immune Therapies in Multiple Myeloma
Kumar, S. K., & Anderson, K. C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0868 · Cited by 66
Self-citationOsteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1
Tai, Y., Cho, S., & Anderson, K. C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01822 · Cited by 68
Self-citationThe Role of Cathepsin B in Pathophysiologies of Non-tumor and Tumor tissues: A Systematic Review
Wang, J., Zheng, M., Yang, X., Zhou, X., & Zhang, S. (2023) · Journal of Cancer · doi:10.7150/jca.86531 · Cited by 70
Díaz-Tejedor, A., Lorenzo-Mohamed, M., Puig, N., García‐Sánz, R., Mateos, M., Garayoa, M., & Paíno, T. (2021) · Cancers · doi:10.3390/cancers13061353 · Cited by 66
Vulnerability of invasive glioblastoma cells to lysosomal membrane destabilization
Joncour, V. L., Filppu, P., Hyvönen, M. L. K., Holopainen, M., Turunen, S. P., Sihto, H. J., Burghardt, I., Joensuu, H., Tynninen, O., Jääskeläinen, J. E., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809034 · Cited by 63
Cui, L., Zhao, L.-P., Ye, J.-Y., Yang, L., Huang, Y., Jiang, X.-P., Zhang, Q., Jia, J.-Z., Zhang, D.-X., & Huang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00031 · Cited by 62
Monoclonal antibody therapy in multiple myeloma
Touzeau, C., Moreau, P., & Dumontet, C. (2017) · Leukemia · doi:10.1038/leu.2017.60 · Cited by 61
Xing, L., Lin, L., Yu, T., Li, Y., Cho, S., Liu, J., Wen, K., Hsieh, P. A., Kinneer, K., Munshi, N. C., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0745-9 · Cited by 61
Self-citationMonoclonal Antibodies for the Treatment of Multiple Myeloma: An Update
Abramson, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123924 · Cited by 59
Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma
Franssen, L. E., Stege, C. A. M., Zweegman, S., van de Donk, N. W. C. J., & Nijhof, I. S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041195 · Cited by 58
Mikhael, J., Richter, J., Vij, R., Cole, C., Zonder, J., Kaufman, J. L., Bensinger, W., Dimopoulos, M., Lendvai, N., Hari, P., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0857-2 · Cited by 54
BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma
Cho, S., Lin, L., Xing, L., Li, Y., Yu, T., Anderson, K. C., & Tai, Y. (2020) · Cancers · doi:10.3390/cancers12061473 · Cited by 57
Self-citationCosta, F., Palma, B. D., & Giuliani, N. (2019) · Cells · doi:10.3390/cells8121632 · Cited by 51
Bisht, K. K., Fukao, T., Chiron, M., Richardson, P. G. G., Atanackovic, D., Chini, E. N., Chng, W. J., de Velde, H. J. V., & Malavasi, F. (2023) · Cancer Medicine · doi:10.1002/cam4.6619 · Cited by 50
Self-citationImmunotherapies targeting CD38 in Multiple Myeloma
Atanackovic, D., Steinbach, M. N., Radhakrishnan, S. V., & Luetkens, T. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1217374 · Cited by 51
Isatuximab: A Review of Its Use in Multiple Myeloma
Frampton, J. E. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00827-0 · Cited by 51
Song, L., Wang, Z., Wang, Y., Guo, D., Yang, J., Chen, L., & Tan, N. (2017) · Molecules · doi:10.3390/molecules22111934 · Cited by 50
Nabar, N. R., Heijjer, C. N., Shi, C.-S., Hwang, I., Ganesan, S., Karlsson, M. C. I., & Kehrl, J. H. (2021) · Autophagy · doi:10.1080/15548627.2021.1954779 · Cited by 48
CD38 as an immunotherapeutic target in multiple myeloma
Bonello, F., D’Agostino, M., Moscvin, M., Cerrato, C., Boccadoro, M., & Gay, F. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1544240 · Cited by 50
Harrison, S. J., Perrot, A., Alegre, A. M., Simpson, D., Wang, M. C., Spencer, A. G., Delimpasi, S., Hulin, C., Sunami, K., Facon, T. T. F., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17499 · Cited by 48
Self-citationTreatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma
Dimopoulos, M.-A., Richardson, P., & Lonial, S. (2022) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2022.01.011 · Cited by 46
Self-citationBonello, F., Mina, R., Boccadoro, M., & Gay, F. (2019) · Cancers · doi:10.3390/cancers12010015 · Cited by 45
Isatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney Transplant
Vincenti, F. G., Bestard, O., Brar, A., Cruzado, J. M., Serón, D., Gaber, A. O., Ali, N. M., Tambur, A. R., Lee, H., Abbadessa, G., et al. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000287 · Cited by 44
Emerging trends and therapeutic applications of monoclonal antibodies
Ramaiah, M. J., Nalluri, H. P., Reddy, P. N., Sainath, S. B., Kumar, N. S. S., Sai Kiran, G. V. S. D., Dhiman, R., Chamarthy, S., Komaragiri, R. R., Manyam, R. R., et al. (2024) · Gene · doi:10.1016/j.gene.2024.148607 · Cited by 45
Yu, T., Chaganty, B., Lin, L., Xing, L., Ramakrishnan, B., Wen, K., Hsieh, P. A., Wollacott, A., Viswanathan, K., Adari, H., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00378-z · Cited by 43
Self-citationFrerichs, K. A., Minnema, M. C., Levin, M., Broijl, A., Bos, G. M. J., Kersten, M. J., Mutis, T., Verkleij, C. P. M., Nijhof, I. S., Maas-Bosman, P. W. C., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005220 · Cited by 42
Zhang, L., Tai, Y., Ho, M., Qiu, L., & Anderson, K. C. (2017) · Experimental Hematology and Oncology · doi:10.1186/s40164-017-0081-6 · Cited by 42
Self-citationCD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience
Frerichs, K. A., Nagy, N. A., Lindenbergh, P. L., Bosman, P., Soto, J. A. M., Broekmans, M. E. C., Groen, R. W. J., Themeli, M., Nieuwenhuis, L., Stege, C. A. M., et al. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1443809 · Cited by 41
New Biological Therapies for Multiple Myeloma
Garfall, A. L. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-050522-033815 · Cited by 47
CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies
de Acha, O. P., Reiman, L. T., Jayabalan, D. S., Walker, Z. J., Bosma, G., Keller, A. L., Parzych, S. E., Abbott, D., Idler, B. M., Ribadeneyra, D., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010162 · Cited by 40
Trudel, S., McCurdy, A. B. R., Louzada, M., Parkin, S., White, D. J., Chu, M. P., Kotb, R. R., Mian, H. S., Othman, I., Su, J., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02703-y · Cited by 41
Comparison of CD38 antibodies in vitro and ex vivo mechanisms of action in multiple myeloma
Kinder, M., Bahlis, N. J., Malavasi, F., de Goeij, B. E. C. G., Babich, A., Sendecki, J. A., Rusbuldt, J. J., Bellew, K. M., Kane, C. M., & van de Donk, N. W. C. J. (2021) · Haematologica · doi:10.3324/haematol.2020.268656 · Cited by 40
Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma
Cho, S., Xing, L., Anderson, K. C., & Tai, Y. (2021) · Cancers · doi:10.3390/cancers13236136 · Cited by 41
Self-citationNagakannan, P., Tabeshmehr, P., & Eftekharpour, E. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.04.001 · Cited by 41
Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities
Yamamoto, L., Amodio, N., Gullà, A., & Anderson, K. C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.606368 · Cited by 40
Self-citationEmerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization
Choi, A. Y., Manook, M., Olaso, D., Ezekian, B., Park, J. B., Freischlag, K., Jackson, A. M., Knechtle, S. J., & Kwun, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.694763 · Cited by 39
Atanackovic, D., Yousef, S., Shorter, C., Tantravahi, S. K., Steinbach, M. N., Cardenas, F. I., Sborov, D. W., Radhakrishnan, S. V., Chiron, M., Miles, R. R., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0536-3 · Cited by 37
Hu, Y., Liu, H., Fang, C., Li, C., Xhyliu, F., Dysert, H., Bodo, J., Habermehl, G. K., Russell, B. E., Li, W., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-1077 · Cited by 37
Self-citationIsatuximab for the treatment of relapsed/refractory multiple myeloma
Richardson, P. G. G., Beksaç, M., Špıčka, I., & Mikhael, J. R. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1841747 · Cited by 37
Self-citationRole of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance
Ho, M., Goh, C. Y., Patel, A. S., Staunton, S., O’Connor, R., Godeau, M., & Bianchi, G. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.05.026 · Cited by 40
Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab
Shen, F., & Shen, W. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221106563 · Cited by 35
CD38 as theranostic target in oncology
Bocuzzi, V., Bridoux, J., Pirotte, M., Withofs, N., Hustinx, R., D’Huyvetter, M., Caers, J., & Marcion, G. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05768-6 · Cited by 36
CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond
Roccatello, D., Fenoglio, R., Sciascia, S., Naretto, C., Rossi, D., Ferro, M., Barreca, A., Malavasi, F., & Baldovino, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114129 · Cited by 34
Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies
Wu, H., & Zhao, X. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.68148 · Cited by 33
Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment
Ho, M., Xiao, A. H., Yi, D., Zanwar, S., & Bianchi, G. (2022) · Current Oncology · doi:10.3390/curroncol29110705 · Cited by 34
Novellis, D. D., Fontana, R., Giudice, V., Serio, B., & Selleri, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010645 · Cited by 34
Bringhen, S., Pour, L., Vorobyev, V. I., Vural, F., Warzocha, K., Benboubker, L., Koh, Y., Maisnar, V., Karlin, L., Pavic, M., et al. (2021) · Leukemia Research · doi:10.1016/j.leukres.2021.106576 · Cited by 31
Self-citationTNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity
Ugamraj, H. S., Dang, K. H., Ouisse, L., Buelow, B., Chini, E. N., Castello, G., Allison, J., Clarke, S., Davison, L. M., Buelow, R., et al. (2022) · mAbs · doi:10.1080/19420862.2022.2095949 · Cited by 31
Schjesvold, F. H., Richardson, P. G. G., Facon, T. T. F., Alegre, A. M., Spencer, A. G., Jurczyszyn, A. J., Sunami, K., Frenzel, L., Min, C., Guillonneau, S., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.253450 · Cited by 30
Self-citationFau, J., Cheikh, R. E., Brillac, C., Koiwai, K., Mace, N., Campana, F., Sémiond, D., & Nguyen, L. (2020) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12561 · Cited by 30
Biological Background of Resistance to Current Standards of Care in Multiple Myeloma
Mogollón, P., Díaz-Tejedor, A., Algarín, E. M., Paíno, T., Garayoa, M., & Ocio, E. M. (2019) · Cells · doi:10.3390/cells8111432 · Cited by 30
CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers
Jiao, Y., Yi, M., Xu, L., Chu, Q., Yan, Y., Luo, S., & Wu, K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1814253 · Cited by 29
IFN-γ and CD38 in Hyperprogressive Cancer Development
Angelicola, S., Ruzzi, F., Landuzzi, L., Scalambra, L., Gelsomino, F., Ardizzoni, A., Nanni, P., Lollini, P., & Palladini, A. (2021) · Cancers · doi:10.3390/cancers13020309 · Cited by 30
Targeting CD38 alleviates tumor-induced immunosuppression
Tai, Y., & Anderson, K. C. (2017) · Oncotarget · doi:10.18632/oncotarget.22992 · Cited by 29
Self-citationEmerging antibodies for the treatment of multiple myeloma
Zagouri, F., Terpos, E., Kastritis, E., & Dimopoulos, M. A. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1186644 · Cited by 29
Xing, L., Wang, S., Liu, J., Yu, T., Chen, H., Wen, K., Li, Y., Lin, L., Hsieh, P. A., Cho, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1621 · Cited by 32
Self-citationEmerging options in multiple myeloma: targeted, immune, and epigenetic therapies
Kumar, S. K. (2017) · Hematology · doi:10.1182/asheducation-2017.1.518 · Cited by 27
Ocio, E. M., Perrot, A., Bories, P., Miguel, J. F. S., Blau, I. W., Karlin, L., Martínez‐López, J., Wang, S., Bringhen, S., Marcatti, M., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01936-7 · Cited by 27
Immunotherapy for the treatment of multiple myeloma
Jung, S., Lee, H., Vo, M.-C., Kim, H., & Lee, J. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.011 · Cited by 29
Novel Agents in Multiple Myeloma
Szalat, R. E., & Munshi, N. C. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000355 · Cited by 27
Self-citationNovel targets for the treatment of relapsing multiple myeloma
Giuliani, N., Accardi, F., Marchica, V., Palma, B. D., Storti, P., Toscani, D., Vicario, E., & Malavasi, F. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1624158 · Cited by 28
Schriewer, L., Schütze, K., Petry, K., Hambach, J., Fumey, W., Koenigsdorf, J., Baum, N., Menzel, S., Rissiek, B., Riecken, K., et al. (2020) · Theranostics · doi:10.7150/thno.38533 · Cited by 27
Metadata
- Authors
- Jiang, H., Acharya, C., An, G., Zhong, M., Feng, X., Wang, L., Dasilva, N., Song, Z., Yang, G., Adrian, F., Qiu, L., Richardson, P., Munshi, N. C., Tai, Y.-T., & Anderson, K. C.
- Affiliations
- Second Military Medical University (CN)
- Dana-Farber Cancer Institute (US)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Corresponding author
- Tai, Y-T
- Venue
- Leukemia
- Published
- 2015-09-04
- Volume
- 30
- Issue
- 2
- Pages
- 399-408
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W1916436059
- Cited by
- 219
- References
- 45
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 17 · 2023: 25 · 2022: 45 · 2021: 33 · 2020: 31 · 2019: 20 · 2018: 11 · 2017: 16 · 2016: 16 · 2015: 1
- FWCI
- 10.59
- Type
- journal article
- Language
- en
- Status
- Retracted
- Update notices
- retraction (2024-10-22)
- Open access
- closed
- Licence
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p01ca078378-15)
- U.S. Public Health Service (R01-050947)
- National Cancer Institute (P01-CA078378, P50CA100707)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- pomalidomide, multiple myeloma, anti-CD38 monoclonal antibody, homotypic aggregation, lysosomal membrane permeabilization, cathepsin B, LAMP1, reactive oxygen species, F(ab')2 fragments, TP53 mutation, lenalidomide resistance, combination therapy, retracted article
- MeSH terms
- Actins, Humans, Lysosomes, Membrane Glycoproteins, Multiple Myeloma, Thalidomide, Genes, p53, Apoptosis, Reactive Oxygen Species, Membrane Microdomains, ADP-ribosyl Cyclase 1, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
